Related references
Note: Only part of the references are listed.A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
Kathleen M. Mullane et al.
CLINICAL INFECTIOUS DISEASES (2019)
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence
Dale N. Gerding et al.
CLINICAL INFECTIOUS DISEASES (2018)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald et al.
CLINICAL INFECTIOUS DISEASES (2018)
Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent &ITClostridium difficile&IT Infection
Vimalanand S. Prabhu et al.
CLINICAL INFECTIOUS DISEASES (2018)
Vancomycin Prophylaxis for Prevention of Clostridium difficile Infection Recurrence in Renal Transplant Patients
Lindsey E. Splinter et al.
ANNALS OF PHARMACOTHERAPY (2018)
Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study
Jennifer L. Kuntz et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2017)
Effect of Oral Capsule-vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection A Randomized Clinical Trial
Dina Kao et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis
David Baur et al.
LANCET INFECTIOUS DISEASES (2017)
A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection
Hannah E. Burton et al.
PHARMACOECONOMICS (2017)
Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France
Maureen Watt et al.
JOURNAL OF MEDICAL ECONOMICS (2017)
Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
Kristen L. Bunnell et al.
OPEN FORUM INFECTIOUS DISEASES (2017)
Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections
Alex Carignan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Cost of hospital management of Clostridium difficile infection in United States-a meta-analysis and modelling study
Shanshan Zhang et al.
BMC INFECTIOUS DISEASES (2016)
Potential Risks and Rewards With Prophylaxis for Clostridium difficile Infection
Stuart Johnson
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents
Nicholas W. Van Hise et al.
CLINICAL INFECTIOUS DISEASES (2016)
Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection A Randomized Clinical Trial
Christine H. Lee et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Burden of Clostridium difficile Infection in the United States
Fernanda C. Lessa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison
Oliver A. Cornely et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Risk Factors for Recurrence, Complications and Mortality in Clostridium difficile Infection: A Systematic Review
Claire Nour Abou Chakra et al.
PLOS ONE (2014)
Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole
Turki Abujamel et al.
PLOS ONE (2013)
Fidaxomicin Preserves the Intestinal Microbiome During and After Treatment of Clostridium difficile Infection (CDI) and Reduces Both Toxin Reexpression and Recurrence of CDI
Thomas J. Louie et al.
CLINICAL INFECTIOUS DISEASES (2012)
Reduced Acquisition and Overgrowth of Vancomycin-Resistant Enterococci and Candida Species in Patients Treated With Fidaxomicin Versus Vancomycin for Clostridium difficile Infection
Michelle M. Nerandzic et al.
CLINICAL INFECTIOUS DISEASES (2012)
Can we identify patients at high risk of recurrent Clostridium difficile infection?
C. P. Kelly
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection
Milagros Gonzales et al.
BMC INFECTIOUS DISEASES (2010)
Skin and Environmental Contamination With Vancomycin-Resistant Enterococci in Patients Receiving Oral Metronidazole or Oral Vancomycin Treatment for Clostridium difficile-Associated Disease
Ajay K. Sethi et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2009)
Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease
Wafa N. Al-Nassir et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Meta-analysis to assess risk factors for recurrent Clostridium difficile infection
K. W. Garey et al.
JOURNAL OF HOSPITAL INFECTION (2008)
Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea
Ju Young Chang et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Share Paper
